Brief: KD Ventures' Pharmnovo Secures Capital Ahead Of Phase 2 Study
09/07/2026 15:46
BRIEF-KD Ventures' Pharmnovo Secures Capital Ahead Of Phase 2 Study July 9 (Reuters) - Kdventures AB KDV.ST:
KD VENTURES: KDVENTURES’ PORTFOLIO COMPANY PHARMNOVO SECURES CAPITAL AHEAD OF PHASE 2 STUDY; HOLDING WRITTEN DOWN
PHARMNOVO COMPLETES CAPITAL RAISE OF ABOUT SEK 39 MILLION WITH EXTERNAL INVESTORS
Source text: ID:nMFNc9jTW0
Further company coverage: KDV.ST
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 772 0920;))
Recent news on Kdventures AB
See all newsRefile: BRIEF-Umecrine Cognition Gets Notice Of Allowance In US
Brief: KDventures' Modus Therapeutics Pauses Enrollment In Phase 2A Study
Brief: KDventures' AnaCardio Raises €62.5 Million
Brief: Kdventures' Umecrine Cognition Gets Two USPTO Notices Of Allowance For Patent Applications
Brief: Kdventures' Modus Therapeutics Carries Out Directed Issue